Business Enterprise R&D Expenditure in the Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations in Mexico stood at 74.91 million USD PPP in 2023 and is expected to decrease annually until 2028. The forecasted data shows a significant downtrend with expenditures falling from 68.59 million USD PPP in 2024 to 44.37 million USD PPP in 2028.
Year-on-year variations indicate:
- 2024-2025: -9.1%
- 2025-2026: -9.8%
- 2026-2027: -10.7%
- 2027-2028: -11.7%
Overall, the compound annual growth rate (CAGR) from 2024 to 2028 is -10.5%, reflecting a consistent decline in R&D expenditure.
Future trends to watch for include global pharmaceutical market dynamics, innovation rates, government policies on R&D incentives, and economic conditions affecting budget allocations. Companies may need to align their R&D strategies with emerging digital transformations and regulatory changes to sustain innovation while managing costs effectively.
